Search results for: Pricing and Reimbursement
Filter search results
Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
26 June 2024
…Wales, and Northern Ireland. We identified and assessed the quality of current evidence on inequalities and explored ways to quantify the magnitude and variation of a selection of these inequalities….
Around the World in HTAs: Kenya – Riding the Waves of Change
19 May 2025
…Health Benefits Package and Advisory Panel (HBPAP) was established and tasked to develop an essential and affordable UHC benefit package and advise on a framework for HTA institutionalisation in Kenya….
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…R&D and the risks in drug development is a challenging task. Peer-reviewed literature documenting the relationship between industry revenues and drug development is limited and outdated. And the R&D ecosystem…
Around The World in HTAs: Türkiye – The bumpy road toward transformation
31 January 2024
…established in 2012 and was later re-named as Research Development and Health Technology Assessment Department (HTAD). Additionally, the Turkish Medicines and Medical Devices Agency (TMMDA) and the HTA department within…
Challenges and Solutions for Budget Impact Analysis of Gene Therapies
10 March 2025
…Germany, Ireland, Italy, Poland, Scotland and Spain. Via a series of literature reviews and discussions with an expert panel, we find four main ways in which the results of BIA…
Prevention in the NHS 10 Year Health Plan: Promise, limits, and the path forward
17 September 2025
…acceptability (e.g. patient attitudes and cultural factors). Vaccine uptake rhetoric vs. the reality, and the 5 A’s framework The discrepancy between high level targets, and the reality of implementation challenges,…
Latest estimates show that 20 people a day die in unrelieved pain across the UK at the end of their lives
26 November 2024
…across the UK is mounting, as populations change. People are living longer, and have increasingly complex and compounding illnesses, meaning that demand for palliative and end of life care will…
The commercial case for investing in ALS
13 November 2025
…and accelerate unlocking disease understanding and novel target and biomarker identification and speed up drug discovery and development. These developments position ALS as a high-impact area for both scientific advancement…
Environmental sustainability in the NHS 10 Year Health Plan: The need for green
29 September 2025
…access to green space and encourage nature-based prescribing Expand and invest in green spaces on NHS grounds and promote green social prescribing through existing GP services Ensure key NHS sites…